Information Provided By: 
Fly News Breaks for July 5, 2017
BLFS
Jul 5, 2017 | 08:37 EDT
As previously reported, Janney Capital upgraded BioLife Solutions to Buy from Neutral with a $5 price target saying Novartis' July 12 FDA hearing is the last step before CTL019 approval and signals the beginning of the regenerative medicine era. Further, with a recurring revenue stream and over 20 products in Phase III trials, the analyst believes growth can accelerate.
News For BLFS From the Last 2 Days
There are no results for your query BLFS
